Top Chinese Think Tank Visits Boston for Study on Health Information Technology
28 November 2018
Earlier this month, Boston Healthcare Associates hosted a delegation from the China Development Research Foundation (CDRF), a public foundation initiated by the Development Research Center of the State Council of the People’s Republic of China, with the mission to provide policy research support for policy making on a national level.
CDRF supports evidence-based policy research, leadership training, high-level forums and symposiums to promote economic cooperation and development, and the promotion of responsible public policy.
The delegation visited Boston to learn more about the role that Health Information Technology (HIT) plays in the healthcare system, how its development has progressed, and future opportunities for improving efficiency and quality of care. Boston, as a global leader in the healthcare and life sciences industry, and home to some of the world’s leading hospitals and community health centers, health IT, and digital health companies, was chosen as one of the field study sites.
The delegation heard from innovative leaders in the HIT space from Partner’s Healthcare, Watson Health, and Harvard Pilgrim Healthcare on day one of the trip during a half day Forum at the Royal Sonesta in Cambridge. Speakers provided the delegation with an in-depth overview of the application of health information technology in healthcare delivery and management.
While in Boston, the delegation also visited and toured Boston Children’s Hospital, the MIT-IBM Watson AI Lab, and Massachusetts General Hospital.
With the Chinese government seeking to improve efficiency and quality of healthcare services and health insurance, especially at the community level, the exchange of information between innovative health organizations is timely.
Boston Healthcare has a deep understanding of the evolving value and access landscape in China. Please contact us for more information.
Recently, Medicare published two CRs associated with the NGS NCD, identifying covered tests and associated CPT and ICD-10 diagnosis codes. These CRs (CR11655 and CR11749) indicated that MSK-IMPACT and MyMRD NGS Panel were nationally covered under the NGS NCD.
G-BA Specifies Procedures for Coverage with Evidence Development- Gene Therapy Zolgensma® First Case
In Germany, the Federal Joint Committee (G-BA) recently amended its rules of assessment procedures to consider new therapies and products without complete clinical data at the time of approval.
The National Health Commission of China recently released a clinical practice to regulate physician prescribing behavior for novel cancer therapies which echoes the government's efforts to control costs.